866-997-4948(US-Canada Toll Free)

Research on China Heparin Industry, 2015

Published By :

Chisult Insight Co., Limited

Published Date : Aug 2015

Category :

Therapeutic Area

No. of Pages : 92 Pages

Currently there are 4 major productss in the global low molecular heparin preparation market: SNY’s enoxaparin sodium, Pfizer’s dalteparin sodium, GSK’s nadroparin calcium and LEO’s tinzaparin sodium. Among which, enoxaparin remains the best –selling product even though its sales amount continued to decline in recent years.

Though enoxaparin always dominates the international heparin preparation market, low molecular heparin calcium is more competitive in China. Low molecular heparin calcium ranked the first position in the usage among sample hospitals in 2014, and has achieved a CAGR of 23% in the past 8 years. Moreover, enoxaparin, heparin sodium and low molecular heparin sodium ranked from 2nd to 4th respectively. These 4 products accounts for 63.6% in Chinese anticoagulant market in 2014.

There are 7 major players in Chinese low molecular heparin calcium market, 6 of them are domestic enterprises. Enoxaparin sodium was imported from SNY in 2003 and in 2006 the generic drug produced by Jiuyuan Gene Engineering Co., Ltd came into market. Currently there are 4 domestic enterprises with volume production. The sales amount of enoxaparin in city public hospitals reached RMB 153 million in 2014. 

In 2014, GSK, Changshan Biochemical Pharmaceutical and Hefei Zhaoke were top3 enterprises in the domestic low molecular heparin calcium market, with total market share of 88.7% in 2014. GSK is the leading enterprises in this segment for a long time, but its growth has slowed down in recent 2 to 3 years. Changshan’s product achieved rapid development relying on independent pricing, which is gradually becoming the import substitution product.

In May 2015, Qianhong Bio-Pharma received the approval letter of enoxaparin sodium API and injection from CFDA. This made Qianhong the 5th enterprises for producing enoxaparin sodium in domestic market. (Time to volume production is still uncertain).

In July 2015, Dongcheng became the third enterprise that get approval of nadroparin, the other two are GSK (RLD) and Nanjing King-Friend (in April 2015). This is the company’s first low molecular heparin preparation product.

1. Executive Summary
1.1 Definition & Classification
1.2 Industry Chain

2. Global Heparin Market
2.1 Supply & Demand
2.3 Market Competition
2.4  Market Forecast

3. Development of Heparin API Industry in China
3.1 Development Environment of Heparin Industry in China
3.1.1 Related Policies
3.1.2 Technical Requirements
3.1.3 Capital Barrier
3.2 Market Status
3.3 Market Supply & Demand
3.4 Competition Pattern
3.5 Import & Export
3.5.1 Export
3.5.2 Import
3.6 Development Prospect and Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2  Low Molecular Heparin Preparation
4.2.1 Low Molecular Heparin Calcium Preparation
4.2.2 Low Molecular Heparin Sodium Preparation
4.3 Unfractionated Heparin Preparation
4.4 Development Prospect and Forecast

5. Key Heparin Enterprises in China
5.1 Hepalink
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Clients and Suppliers
5.1.7 Heparin Business
5.2 Qianhong Bio-Pharma
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients and Supplies
5.2.7 Heparin Business
5.2.8 Prospective
5.3 Dongcheng Biochemicals
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R& D and Investment
5.3.6 Clients
5.3.7 Heparin Business
5.3.8  Prospective
5.4 Changshan Biochemical Pharmaceutical
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R& D and Investment
5.4.6 Clients and Suppliers
5.4.7 Prospective
5.5 Tianjin Chase Sun
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R& D and Investment
5.5.6 Clients and Suppliers
5.5.7 Heparin Business
5.5.8 Prospective
5.6 Nanjing King-Friend
5.6.1 Profile
5.6.2 Operation and Prospective
5.7 Jiangsu Wanbang
5.7.1 Wanbang Biopharmaceuticals
5.7.2 Operation and Prospective
5.8 Hefei Zhaoke
5.8.1 Profile
5.8.2 Opearation
5.8.3 Heparin Business
5.9 Sciprogen
5.9.1 Profile
5.9.2 Opearation
5.9.3 Heparin Business
5.10 Hainan Unipul Pharmaceutical Co., Ltd.
5.10.1 Profile
5.10.2 Opearation
5.10.3 Heparin Business
5.11 Hangzhou Jiuyuan Gene Engineering Co., Ltd.
5.11.1 Profile
5.10.2 Opearation
5.11.3 Heparin Business
5.11 Techpool
5.11.1 Profile
5.10.2 Opearation
5.11.3 Heparin Business

6. Industry Main Indicator

List of Table

Application of Heparin Preparations
Heparin Industry Chain
Market Size of Heparin Preparation Worldwide and YoY Growth, 2006-2014
Performance Comparison Between Low Molecular Weight Heparin Preparation and Unfractionated Heparin Preparation
Market Size of Global Heparin Preparations by Product, 2010-2014
Regional Distribution of Heparin Preparations Worldwide, 2014
Global Heparin API Demand and YoY Growth, 2007-2014
Major Heparin Preparation Producers Worldwide
Sales of Major Heparin Preparation Brands Globally, 2010-2014
Global Market Size of Heparin Preparations, 2012-2016
Global Demand for Heparin API, 2011-2016
Gross Margin of Major Heparin API Producers in China, 2008-2015
Pig Slaughtering Volume and Breeding Stock in China, 2008-2014
Capacity of Heparin Crude Products in China, 2008-2014
Export Average Price of Heparin and Salt in China, 2008-2014
Capacity, Sales Volume and Certification of Major Heparin API Enterprises in China, 2014
Export Volume and Export Value of Heparin and Its Salts in China, 2008-2015
Export Price of Heparin and Its Salts in China, 2008-2015
Top 10 Export Destinations of China’s Heparin and Its Salts by Export Value, 2012-2015
Top 10 Export Enterprises of Heparin and Its Salts in China by Export Value, 2014
Import Volume, Import Value and Unit Price of Heparin and Its Salts in China, 2008-2015
Heparin Sodium API Projects Proposed/Under Construction in China as of Jun. 2014-2015
Market Size of Heparin Preparations in China and YoY Growth, 2007-2014
Market Share of Heparin Preparations in China by Product, 2014
Market Size of Low Molecular Weight Heparin Preparation in China, 2009-2014
Major Low Molecular Heparin Calcium Preparation Enterprises in China and Their Bidding Prices, 2014
Distribution of Low Molecular Heparin Calcium Market in China by Enterprises
Major Low Molecular Heparin Sodium Preparation Enterprises in China and Their Bidding Prices, 2014
Major Heparin Sodium Preparation Enterprises in China and Their Selling Prices, 2008-2014
Market Size of Heparin Preparation in China and YoY Growth, 2012-2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *